Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure (GOAL-HF2)

6. November 2026 aktualisiert von: AnaCardio AB

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of 2 Dose Levels of the Oral Ghrelin Receptor Agonist AC01 Over 12 Weeks in Patients With Chronic Advanced Heart Failure With Reduced Ejection Fraction (HFrEF)

The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.

Studienübersicht

Detaillierte Beschreibung

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study designed to evaluate the safety and efficacy of the ghrelin-receptor agonist AC01 compared to placebo in participants with chronic advanced HFrEF. Approximately 400 participants will be randomized to 1 of 3 treatment arms: 3 milligram (mg) AC01, 1 milligram (mg) AC01, or placebo twice daily for 12 weeks. The primary objective is to evaluate the effect of AC01 compared to placebo on cardiac structure and function assessed by echocardiography.

Studientyp

Interventionell

Einschreibung (Geschätzt)

400

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Blagoevgrad, Bulgarien, 2700
        • Rekrutierung
        • Multi-Profile Hospital for Active Treatment (MHAT) - Hospital Puls
      • Burgas, Bulgarien, 8000
        • Rekrutierung
        • Medical Center I - Burgas
      • Pleven, Bulgarien, 5800
        • Rekrutierung
        • Medical Center Medconsult Pleven
      • Trois-Rivières, Kanada, G9A 4P3
        • Rekrutierung
        • Diex Recherche Trois-Rivières
    • Québec (QC)
      • Sherbrooke, Québec (QC), Kanada, J1L 0H8
        • Rekrutierung
        • Diex Recherche Sherbrooke
      • Oświęcim, Polen, 32600
        • Rekrutierung
        • Medicome Sp z o.o. Oswiecimskie Centrum Medyczne
      • Gothenburg, Schweden, 41345
        • Rekrutierung
        • Sahlgrenska Universitetssjukhuset
      • Prešov, Slowakei, 08001
        • Rekrutierung
        • MUDr. Daniela Viňanská Interná a kardiologická ambulancia, Medispol, s.r.o
      • Palma, Spanien, 07198
        • Rekrutierung
        • Hospital SON LLATZER
      • Klatovy, Tschechien, 33901
        • Rekrutierung
        • Kardio Michal Čepelák, s.r.o.
    • California
      • Van Nuys, California, Vereinigte Staaten, 91405-2272
        • Rekrutierung
        • Progressive MD, InvivoCure
    • Florida
      • Crystal River, Florida, Vereinigte Staaten, 34429
        • Rekrutierung
        • Nature Coast Clinical Research
    • Illinois
      • Schaumburg, Illinois, Vereinigte Staaten, 60173
        • Rekrutierung
        • Chicago Cardiology Institute
    • Pennsylvania
      • Camp Hill, Pennsylvania, Vereinigte Staaten, 17011
        • Rekrutierung
        • Capital Area Research, LLC - Camp Hill

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 85 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Key Inclusion Criteria:

  • History of Chronic Heart Failure (CHF) diagnosed greater than or equal to (>=6) months before screening, and in NYHA Class II to IV at screening.

  • Chronic advanced HFrEF defined as:

    • LVEF less than or equal to (<=) 35 percentage (%) by local reading >=6 months before screening or a record of LVEF qualitatively described as severely reduced or moderately-severely reduced >=6 months before screening, and
    • LVEF <=35% at the screening echocardiography (confirmed by core lab), and
    • no known LVEF greater than (>) 35% (or qualitatively described as less than moderately-severely reduced) between the 2 readings.
  • Sinus rhythm or permanent, persistent, or paroxysmal atrial fibrillation flutter (AFF) (AFF at screening is capped at maximum 15% of participants enrolled) with mean resting heart rate of >=55 and <=90 beats per minute (bpm) at screening, and >=50 and <=95 bpm at randomization, regardless of rhythm.

  • NT-proBNP >=400 picograms per milliliter (pg/mL) in sinus rhythm and >=800 pg/mL in AFF at screening (confirmed by central laboratory).

  • Transvenous implantable cardioverter-defibrillator (ICD) for primary prevention with back-up pacing set at 40 bpm.

  • Treated with optimal, stable, medical therapy for HF consistent with prevailing local and international guidelines unless contraindicated or not tolerated, as judged and documented by the investigator.

Key Exclusion Criteria:

  • Any acute or serious co-morbid condition that could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.
  • Admitted to hospital with the primary reason of HF within 24 hours before randomization or currently hospitalized with the primary reason of HF for more than 10 days. Current hospitalization (>24 hours and <=10 days) is capped at a maximum of 15% of participants enrolled.
  • Acute coronary syndrome, stroke or transient ischemic attack, severe ventricular arrhythmia, or major cardiac intervention, percutaneous coronary intervention, valvuloplasty/other cardiac valve repair or implantation, or cardiac surgery within 60 days before randomization.
  • Systolic blood pressure >130 or ˂90 millimeters of mercury (mmHg) at screening, or >140 or ˂85 mmHg at randomization.
  • Uncontrolled diabetes mellitus, defined as Hemoglobin A1c (HbA1c) >=9.0% (>=75 millimoles per mole [mmol/mol]) at screening, or severe complications of diabetes.
  • Body weight <50 kilogram (kg) or body mass index (BMI) <18 kilograms per square meter (kg/m^2) or >45 kg/m^2 at screening.
  • Any of the following electrocardiogram (ECG) findings at screening: Corrected QT interval using Fridericia's formula (QTcF) >450 milliseconds (ms), 1st degree atrioventricular (AV) block with PQ >240 ms, or AV block 2nd or 3rd degree.
  • History of aborted cardiac arrest, sustained ventricular tachycardia, or Torsades-de Pointes, or congenital long QT syndrome. Family history of sudden cardiac death, unexplained death, long QT syndrome, or death from a primary dysrhythmia.
  • Cardiac resynchronization therapy, Cardiac Contractility Modulation, or pacemaker device other than the back-up pacing function of the ICD.
  • Mechanical hemodynamic support, kidney support, or ventilation within 7 days before randomization.
  • Treatment with i.v. inotropes, i.v. vasodilators, or i.v. vasopressors within 3 days before randomization.
  • Treatment with any i.v. diuretics or supplemental oxygen within 6 hours before randomization.
  • Use of any drugs or substances known to be strong inducers of Cytochrome P450 3A4 (CYP3A4) enzyme within 28 days before randomization or planned to be used during the study period or strong inhibitors of CYP3A4 within 7 days before randomization or planned to be used during the study period.
  • Use of any drug that is known to prolong the QT interval (for example, sotalol, dofetilide, macrolides, some antidepressants, and some antipsychotics) within 28 days before randomization or planned to be used during the study period.
  • Treatment changes in glucose lowering therapy within 28 days before randomization.
  • Estimated glomerular filtration rate (eGFR) <20 milliliters per minute per 1.73 square meters (mL/min/1.73 m2) according to the Chronic Kidney Disease Epidemiology Collaboration formula, planned renal replacement therapy within the next 6 months, or receiving dialysis at screening.
  • Serum potassium <3.5 or >5.2 milliequivalents per liter (mEq/L) at screening.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 *upper limit of normal (ULN) or total bilirubin >2 * ULN, or known cirrhosis, severe liver, or pancreatic disease at screening.
  • Use of any anti-arrhythmic drugs within 28 days before randomization or planned to be used during the study period, except for amiodarone, ivabradine, digoxin, and beta blockers.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: AC01 3 mg

Participants will receive AC01 orally twice daily (BID) for 12 weeks.

AC01 tablets for oral administration.

Experimental: AC01 1 mg

Participants will receive AC01 orally BID for 12 weeks.

AC01 tablets for oral administration.

Placebo-Komparator: Placebo

Participants will receive matching placebo orally BID for 12 weeks.

AC01 matching placebo tablets for oral administration.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Absolute Change from Baseline in Composite Echocardiography Z-Score at Week 12
Zeitfenster: Baseline and Week 12

The composite echocardiography Z-score integrates left ventricular stroke volume (LVSV), left ventricular end systolic volume (LVESV), left ventricular ejection fraction (LVEF), and left atrial minimal volume index (LAVImin).

Baseline and Week 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Absolute Change from Baseline in LVSV at Week 12
Zeitfenster: Baseline and Week 12
Baseline and Week 12
Absolute Change from Baseline in LVEF at Week 12
Zeitfenster: Baseline and Week 12
Baseline and Week 12
Absolute Change from Baseline in LVESV at Week 12
Zeitfenster: Baseline and Week 12
Baseline and Week 12
Absolute Change From Baseline in LAVImin at Week 12
Zeitfenster: Baseline and Week 12
Baseline and Week 12
Absolute Change from Baseline in N-terminal prohormone of Brain Natriuretic Peptide (NT-proBNP)
Zeitfenster: Baseline and Week 12
Baseline and Week 12
Number of Participants With Death, Cardiovascular Death, Hospitalization, Cardiovascular Hospitalization, Heart Failure Hospitalization, Heart Failure Events, Other Adjudicated Events, and Listed for Heart Transplantation
Zeitfenster: At Week 12
At Week 12
Change From Baseline in Guideline-directed Medical Therapy (GDMT) Use for HFrEF at Week 12
Zeitfenster: Baseline and Week 12
Baseline and Week 12
Absolute Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Zeitfenster: Baseline and Week 12
Baseline and Week 12
Number of Participants With Dialysis
Zeitfenster: At Week 12
At Week 12
Absolute Change From Baseline in New York Heart Association (NYHA) Class
Zeitfenster: Baseline and Week 12
Baseline and Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs)
Zeitfenster: From first dose of study drug up to end of follow up (up to Week 16)
From first dose of study drug up to end of follow up (up to Week 16)
Absolute Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) at Week 12
Zeitfenster: Baseline and Week 12

The KCCQ is a validated, 23-item, self-administered questionnaire designed to assess health status in participants with congestive heart failure. It evaluates six domains: symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability. Each domain score is transformed to a scale of 0 to 100, with higher scores indicating better health status. The KCCQ-TSS is derived from the domain scores.

Baseline and Week 12
Absolute Change From Baseline in Patient Global Impression of Severity (PGIS) at Week 12
Zeitfenster: Baseline and Week 12

PGIS is 1-item questionnaire used to rate the severity of a specific condition. Participants record their perceived severity of heart failure (HF) symptoms, specifically shortness of breath, fatigue, and swelling, and choose 1 response that best described the extent of their symptoms based on a 5-point scale. Response options include none, mild, moderate, severe, and very severe. Higher PGIS scores indicate more severe HF symptoms; lower scores indicate less severe symptoms.

Baseline and Week 12
Patient Global Impression of Change (PGIC) at Week 12
Zeitfenster: At Week 12

The PGIC questionnaire is administered to assess the participant's impression of change in HF symptoms since the initiation of study treatment, specifically changes in shortness of breath, fatigue, and swelling. Participants select one response to describe the overall change (if any) in HF symptoms on a 7-category scale: 7=very much improved, 6 =much improved, 5 =minimally improved, 4 =no change, 3 =minimally worse, 2 =much worse, and 1 =very much worse. Higher PGIC scores indicate greater improvement in HF symptoms, while lower scores indicate worsening or no change.

At Week 12
Absolute Change from Baseline in Council on Nutrition Appetite Questionnaire (CNAQ) Total Score
Zeitfenster: Baseline and Week 12

The CNAQ is an 8-item, self-administered questionnaire used to assess appetite over time. Each item is scored on a scale of 1 to 5, and the total score is calculated as the sum of all item scores. The instrument has demonstrated acceptable psychometric properties, including internal consistency, construct validity, and predictive validity, for assessing appetite in participants with heart failure. Higher CNAQ scores indicate better appetite.

Baseline and Week 12
AUC,ss: Area Under the Concentration-Time Curve at Steady State of AC01 and its Metabolite M6
Zeitfenster: At Week 4 and Week 12

Population pharmacokinetic parameters

At Week 4 and Week 12
Cmax,ss: Maximum Observed Concentration at Steady State of AC01 and its Metabolite M6
Zeitfenster: At Week 4 and Week 12

Population pharmacokinetic parameters

At Week 4 and Week 12
Tmax,ss: Time to Reach Maximum Concentration at Steady State
Zeitfenster: At Week 4 and Week 12

Population pharmacokinetic parameters

At Week 4 and Week 12
Ctrough: Trough concentration at steady state of AC01 and its Metabolite M6
Zeitfenster: At Week 4 and Week 12

Population pharmacokinetic parameters

At Week 4 and Week 12
Rac (Cmax): Accumulation Ratio of Cmax for AC01 and its Metabolite M6
Zeitfenster: At Week 4 and Week 12

Population pharmacokinetic parameters. Accumulation ratio of Cmax calculated as Cmax at Week 12/Cmax at Week 4.

At Week 4 and Week 12
Rac (AUC): Accumulation Ratio of AUC for AC01 and its Metabolite M6
Zeitfenster: At Week 4 and Week 12

Population pharmacokinetic parameters. Accumulation ratio of AUC calculated as AUC at Week 12/AUC at Week 4.

At Week 4 and Week 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. November 2026

Primärer Abschluss (Geschätzt)

30. Juli 2028

Studienabschluss (Geschätzt)

30. August 2028

Studienanmeldedaten

Zuerst eingereicht

4. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

8. Mai 2026

Zuerst gepostet (Tatsächlich)

13. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • AC01-02
  • 2025-524469-25-00 (Ctis)
  • PIP number (Andere Kennung: EMA/PE/0000267875)
  • 2025 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Individual de-identified participant data will be shared with qualified scientific and medical researchers whose proposed use of data has been approved by the study executive committee, beginning 9 months and ending 36 months following article publication. Proposals should be directed to the Central Contact Person.

IPD-Sharing-Zeitrahmen

Links to the Study Protocol and Statistical Analysis Plan will be made available on ClinicalTrials.gov

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren